logo
Why Super Micro Computer's Upside Could Trigger a Short Squeeze

Why Super Micro Computer's Upside Could Trigger a Short Squeeze

Entrepreneur03-06-2025
This story originally appeared on MarketBeat
There's an often forgotten strategy that has made millionaires in the past, when it comes to the stock market, signs of interest (or lack thereof) for any stock can guide regular investors into some of the best opportunities that most others leave behind due to the simple fact that they are less understood than the typical methods employed by retail investors. This strategy involves a contrarian, high-risk, and high-reward point of view.
[content-module:CompanyOverview|NASDAQ:SMCI]
More specifically, this strategy is called riding up a short squeeze, which was at the heart of the so-called 'Meme stock mania' that turned markets red hot during the cheap money and low interest rates era after the COVID-19 pandemic. The reason these stocks reached stratospheric valuations is simple: the short sellers were cornered into a forced position to close out and cut their losses.
Now, closing a short position, whether for loss-cutting or profit-taking, involves buying back the borrowed stock that was sold. This means additional buying pressure, and that leads investors to an opportunity to see outsized returns when they can catch a stock with high short interest and a reasonable theme that could put pressure on these sellers. This is exactly where shares of Super Micro Computer Inc. (NASDAQ: SMCI) come into play.
Why Super Micro Computer Stock?
Since buyers' focus is on running the stock to a choke point and triggering what's known as a 'short squeeze,' whereby short sellers are forced to close out their positions and buy the stock in the process, investors should first check what the short interest looks like for Super Micro Computer stock today.
As of May 2025, up to 20.9% of the available shares in the market for this company were held in short positions, a significant level by any measure taken in the technology sector. This is important because if the stock can maintain the upside momentum, as seen in the recent 20.9% monthly performance, then it's only a matter of time before a short squeeze is triggered.
That would mean up to $4.4 billion worth of short positions could be closed out on the buy side, a significant tailwind to help the stock return to its previous highs, which were achieved before the negative media began to put a ceiling on the company's future prospects.
Knowing that this setup could have a similar outcome to that of the meme stock mania, some institutional buyers have decided to take action, also noticing that Super Micro Computer stock trades at only 40% of its 52-week high, thereby creating a fantastic risk-to-reward ratio today.
What Short Sellers Fear Most
It's not only the $4.3 billion that institutional investors have bought in Super Micro Computer stock over the past quarter, but also the deep fundamental developments currently working in favor of the company's future financials and valuations.
[content-module:Forecast|NASDAQ:SMCI]
One such development is that the Saudi government has decided to partner with Super Micro Computer due to its services and equipment, which will be used to build the nation's artificial intelligence infrastructure. More than that, the power of Super Micro Computer's liquid-cooling system for data centers attracted another formidable partnership.
NVIDIA Co. (NASDAQ: NVDA) posted a stellar quarter recently, showing continued demand for the chipmaker's Blackwell product line, which is directly tied to these liquid-cooling services that Super Micro Computer offers. Before any Wall Street analysts come into play and forecast the financial impacts of these developments, here's what investors need to know.
As earnings per share (EPS) forecasts stand today, Wall Street analysts see Super Micro Computer delivering up to $0.94 in EPS by the fourth quarter of 2025, a threefold jump from today's reported $0.31 in EPS. This matters because where EPS growth goes, so does the stock price, essentially.
Faced with this wall of upside ahead of them, short sellers who decide to stay for a fight will likely be forced to the point of maximum pain, where liquidating their positions will follow (resulting in buying the stock). With this in mind, those looking to gain exposure to Super Micro Computer are sure to get a terrific bargain at today's prices.
This might also be the reason why Nehal Chokshi, an analyst at Northland Securities, placed a valuation of up to $59 per share on the stock in early May 2025. Now, despite all the trade tariffs and S&P 500 uncertainty that have occurred since then, this analyst has not changed his view on Super Micro Computer, which is also a sign of confidence.
Given the stock's decline from its current level, this valuation target would imply a potential upside of up to 44.6%. This gap is the last stand for short sellers to justify holding onto $4.4 billion worth of short positions today. If the stock validates this valuation target, that balance will likely serve as another catalyst to drive the stock even higher.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts
Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts

Yahoo

time7 minutes ago

  • Yahoo

Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts

Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the most promising penny stocks under $5. On August 8, Raymond James lowered the firm's price target on Relay Therapeutics to $19 from $29, while keeping a Strong Buy rating on the shares. This sentiment followed Relay Therapeutics' Q2 2025 results, where OpEx was down 16% sequentially following strategic cost-cutting initiatives. Relay Therapeutics reported a net loss of $70.4 million, or $0.41 per share, in Q2 2025, which was an improvement compared to the net loss of $92.2 million, or $0.69 per share, in Q2 2024. Revenue for the quarter was $0.7 million, which was an increase from zero revenue in the same period last year. A chemist arranging containers of compounds, ready for the commercialization process. This quarter also featured the initiation of the Phase 3 ReDiscover-2 trial for RLY-2608 in Q2 2025. At the 2025 American Society for Clinical Oncology/ASCO Annual Meeting, updated interim data from the Phase 1b study for RLY-2608 were presented. In addition to oncology, Relay Therapeutics is continuing to execute its ongoing Phase 1 clinical trial for vascular malformations. Relay Therapeutics Inc. (NASDAQ:RLAY) is a clinical-stage precision medicines company that transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Warren Buffett Buys a Beaten Down Healthcare Stock: Should You Follow?
Warren Buffett Buys a Beaten Down Healthcare Stock: Should You Follow?

Yahoo

time7 minutes ago

  • Yahoo

Warren Buffett Buys a Beaten Down Healthcare Stock: Should You Follow?

Warren Buffett has struck again – this time in healthcare's rubble. Berkshire Hathaway (NYSE: BRK.B) recently disclosed a five million share position in United Healthcare Group (NYSE: UNH), the nation's largest health insurer. The timing is quintessentially Buffett. UNH shares have plummeted more than 50% from their all-time highs, battered by regulatory pressures and industry headwinds. While most investors flee the carnage, the Oracle of Omaha is doing what he does best – hunting for value in the wreckage. But as with everything Buffett does, context matters. Putting Things in Perspective The United Healthcare position is estimated to be worth around US$1.6 billion based on Berkshire's five million share purchase. That's a sizable sum of money by any measure. Here's what you need to know: Berkshire Hathaway's stock portfolio is worth close to US$295 billion. Therefore, the UNH position is less than 0.6% of the company's overall stock holdings. In contrast, Berkshire's largest position is actually Apple (NASDAQ: AAPL), valued at US$65 billion – representing more than a fifth of the total stock portfolio. Put simply, while the United Healthcare investment grabbed headlines, it wouldn't be moving Berkshire's needle anytime soon. Beyond that, there's a crucial question: did Buffett actually make this call? The Real Decision Makers Every Berkshire Hathaway stock purchase gets dissected as if it came straight from Warren Buffett himself. But the Oracle doesn't fly solo anymore. Berkshire brought on Todd Combs in 2010, followed by Ted Weschler in 2012. Both serve as investment managers with significant autonomy. Initially, Buffett allocated US$2 billion to each manager. By 2017, that figure had quintrupled to US$10 billion per person. Given this structure, the US$1.6 billion UNH bet could be from either Combs or Weschler – not Buffett himself. Get Smart: Look before you leap Context matters when it comes to investing. If you jump in and buy shares without understanding the full picture, you could get hurt in the process. For Berkshire, even if the UnitedHealth investment doesn't work out, you won't see the company sweating over a position worth less than 0.6%. Does the same apply to you? That's food for thought if you decide to pull the trigger. Dive into the future of technology with our newest FREE report, 'The Rise of Titans.' Discover how the big 7 US tech stocks can be your ticket to huge long-term gains. Download your copy today and see how easy it is to supercharge your portfolio. Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses! Disclosure: Chin Hui Leong owns shares of Apple and Berkshire Hathaway The post Warren Buffett Buys a Beaten Down Healthcare Stock: Should You Follow? appeared first on The Smart Investor. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth
Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth

Yahoo

time7 minutes ago

  • Yahoo

Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth

Clover Health Investments Corp. (NASDAQ:CLOV) is one of the most promising penny stocks under $5. On August 7, Canaccord lowered the firm's price target on Clover Health to $4.10 from $4.50, while keeping a Buy rating on the shares. The firm said the company reported solid Q2 2025 results, but the insurance benefit expense ratio came in higher than expected, which was of some concern. In Q2, the company's Medicare Advantage membership grew by over 30% year-over-year, and the insurance revenue increased by 34% to $470 million. Clover Health Investments' technology-first care model, which includes the Clover Assistant platform, showed a 15% reduction in hospitalizations and an 18% reduction in readmissions for patients with chronic obstructive pulmonary disease/COPD. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company is now well-positioned for future growth with a 4-star payment year in 2026, which is expected to provide a financial tailwind. Clover Health is also expanding its technology platform to other risk-bearing entities, potentially opening up additional revenue streams. Clover Health Investments Corp. (NASDAQ:CLOV) is a company that provides medicare advantage plans in the US. It operates Clover Assistant, which is a software platform to execute strategy by enabling physicians to detect, identify, and manage chronic diseases earlier than they otherwise could. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store